Terms: = Leukemia AND CALR, ENSG00000179218, 811, P27797, SSA, RO, FLJ26680, cC1qR AND Prognosis
62 results:
1. Comprehensive characterization of immunogenic cell death in acute myeloid leukemia revealing the association with prognosis and tumor immune microenvironment.
Chen Y; Qiu X; Liu R
BMC Med Genomics; 2024 Apr; 17(1):107. PubMed ID: 38671491
[TBL] [Abstract] [Full Text] [Related]
2. Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.
Ferrer-Marín F; Hernández-Boluda JC; Alvarez-Larrán A
Br J Haematol; 2024 May; 204(5):1605-1616. PubMed ID: 38586911
[TBL] [Abstract] [Full Text] [Related]
3. [Clinical and prognostic characteristics of pediatric acute myeloid leukemia with myelodysplasia-related changes under different diagnostic criteria].
Zhang RR; Ruan M; Liu TF; Wang SC; Zhang XY; Qi BQ; Zhu XF; Zhang L
Zhonghua Er Ke Za Zhi; 2024 Mar; 62(3):250-255. PubMed ID: 38378287
[No Abstract] [Full Text] [Related]
4. Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management.
Tefferi A; Vannucchi AM; Barbui T
Am J Hematol; 2024 Apr; 99(4):697-718. PubMed ID: 38269572
[TBL] [Abstract] [Full Text] [Related]
5. STAT5a and SH2B3 novel mutations display malignancy roles in a triple-negative primary myelofibrosis patient.
Zhang S; Yan J; He L; Jiang Z; Jiang H
Cancer Gene Ther; 2024 Mar; 31(3):484-494. PubMed ID: 38135698
[TBL] [Abstract] [Full Text] [Related]
6. [Clinical characteristics and prognosis of patients with therapy-related myelodysplastic syndrome and acute myeloid leukemia arising from malignant tumors].
Xu XS; Ding H; Zhang X; Liao Y; Li H; Liu QY; Liu JZ; Zhang L; Huang J; Gong YP; Ma HB; Xiang B; Dai Y; Hou L; Shuai X; Niu T; Wu Y
Zhonghua Xue Ye Xue Za Zhi; 2023 Sep; 44(9):742-748. PubMed ID: 38049318
[No Abstract] [Full Text] [Related]
7. [Clonal hematopoiesis and its evolution of myeloproliferative neoplasms].
Zhang L; Dong H
Zhonghua Yi Xue Za Zhi; 2023 Dec; 103(45):3608-3614. PubMed ID: 38018059
[TBL] [Abstract] [Full Text] [Related]
8. Enhancing information on stage at diagnosis for childhood cancer in Africa.
Liu B; Abraham N; Chitsike I; Sylvie CGL; Kambugu J; Stévy NMA; Pondy AHO; Renner L; Parkin DM
Pediatr Blood Cancer; 2023 Oct; 70(10):e30555. PubMed ID: 37432023
[TBL] [Abstract] [Full Text] [Related]
9. Cytological Diagnosis of Classic Myeloproliferative Neoplasms at the Age of Molecular Biology.
Combaluzier S; Quessada J; Abbou N; Arcani R; Tichadou A; Gabert J; Costello R; Loosveld M; Venton G; Berda-Haddad Y
Cells; 2023 Mar; 12(6):. PubMed ID: 36980287
[TBL] [Abstract] [Full Text] [Related]
10. Novel Molecular Insights into Leukemic Evolution of Myeloproliferative Neoplasms: A Single Cell Perspective.
Rontauroli S; Carretta C; Parenti S; Bertesi M; Manfredini R
Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499582
[TBL] [Abstract] [Full Text] [Related]
11. Molecular prognostication in Ph-negative MPNs in 2022.
Vannucchi AM; Guglielmelli P
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):225-234. PubMed ID: 36485130
[TBL] [Abstract] [Full Text] [Related]
12. Clinicopathologic spectrum of myeloid neoplasms with concurrent myeloproliferative neoplasm driver mutations and SRSF2 mutations.
Tashakori M; Khoury JD; Routbort MJ; Patel KP; Wang SA; Ok CY; El-Hussein S; Kanagal-Shamanna R; Luthra R; Hu S; Lin P; Pemmaraju N; Bose P; Verstovsek S; Bueso-Ramos CE; Medeiros LJ; Loghavi S
Mod Pathol; 2022 Nov; 35(11):1677-1683. PubMed ID: 35690645
[TBL] [Abstract] [Full Text] [Related]
13. [Establishment and Validation of Immune Risk Score for Predicting Survival of Patients with Acute Myeloid leukemia].
Hu F; Wang Y; Zhang Y; Zeng Y; Wang SQ; Pan XY; Yang TH; Liu QF; Liang Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Apr; 30(2):327-333. PubMed ID: 35395958
[TBL] [Abstract] [Full Text] [Related]
14. Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN.
Pasca S; Chifotides HT; Verstovsek S; Bose P
Int Rev Cell Mol Biol; 2022; 366():83-124. PubMed ID: 35153007
[TBL] [Abstract] [Full Text] [Related]
15. Lab tests for MPN.
Moncada A; Pancrazzi A
Int Rev Cell Mol Biol; 2022; 366():187-220. PubMed ID: 35153004
[TBL] [Abstract] [Full Text] [Related]
16. Myeloproliferative Neoplasms with Monocytosis.
Morsia E; Gangat N
Curr Hematol Malig Rep; 2022 Feb; 17(1):46-51. PubMed ID: 34773576
[TBL] [Abstract] [Full Text] [Related]
17. Clinical characteristics, prognostic factors, and outcomes of patients with essential thrombocythemia in Japan: the JSH-MPN-R18 study.
Hashimoto Y; Ito T; Gotoh A; Nakamae M; Kimura F; Koike M; Kirito K; Wada H; Usuki K; Tanaka T; Mori T; Wakita S; Saito TI; Kada A; Saito AM; Shimoda K; Sugimoto Y; Kurokawa T; Tomita A; Edahiro Y; Akashi K; Matsumura I; Takenaka K; Komatsu N
Int J Hematol; 2022 Feb; 115(2):208-221. PubMed ID: 34727329
[TBL] [Abstract] [Full Text] [Related]
18. [Clinical characteristics and prognosis of
Zhang MX; Shi WZ; Liu JX; Wang CJ; Li Y; Wang W; Jiang B
Beijing Da Xue Xue Bao Yi Xue Ban; 2021 Oct; 53(5):915-920. PubMed ID: 34650294
[TBL] [Abstract] [Full Text] [Related]
19. Integration of Molecular Information in Risk Assessment of Patients with Myeloproliferative Neoplasms.
Loscocco GG; Coltro G; Guglielmelli P; Vannucchi AM
Cells; 2021 Aug; 10(8):. PubMed ID: 34440731
[TBL] [Abstract] [Full Text] [Related]
20. Accelerated Phase of Myeloproliferative Neoplasms.
Shahin OA; Chifotides HT; Bose P; Masarova L; Verstovsek S
Acta Haematol; 2021; 144(5):484-499. PubMed ID: 33882481
[TBL] [Abstract] [Full Text] [Related]
[Next]
